GSK and AnaptysBio Enter Legal Battle Over Cancer Drug Jemperli
GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.
/ 10 items
#GSK↓
AnaptysBio ends UC trial, advances RA program, plans 2026 split
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
Alector Cuts Half Its Workforce After Failed Dementia Drug Trial
Alector announces 49% workforce reduction and discontinuation of latozinemab trials after Phase 3 study fails to show clinical benefit in frontotemporal dementia patients.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.